CliffBio
small molecule

DIFLUPREDNATE

DIFLUPREDNATE

Loss of exclusivity—loss of exclusivity
CompanyCipla →See this company's full patent-cliff portfolio

Drug detail

Brand nameDIFLUPREDNATE
Active ingredientDIFLUPREDNATE
Strength0.05%
Dosage formEMULSION
RouteOPHTHALMIC
ModalitySmall molecule
FDA approvalAugust 2021
Marketing statusRX

More from Cipla

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DIFLUPREDNATE patent cliff — loss of exclusivity — | CliffBio